The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
台湾南部地区不适合移植的多发性骨髓瘤患者接受硼替佐米联合沙利度胺和地塞米松(VTD)或硼替佐米联合美法仑和泼尼松龙(VMP)治疗的成本效益分析
期刊:Journal of Personalized Medicine
影响因子:3
doi:10.3390/jpm12020130
Du, Jeng-Shiun; Kuo, Yi-Chun; Shi, Hon-Yi; Wang, Ming-Chung; Wang, Li-Ying; Chuang, Tzer-Ming; Ke, Ya-Lun; Yeh, Tsung-Jang; Gau, Yu-Ching; Wang, Hui-Ching; Cho, Shih-Feng; Hsiao, Samuel Yien; Liu, Yi-Chang; Hsu, Chin-Mu; Hsiao, Hui-Hua